)
UCB (UCB) investor relations material
UCB Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Portfolio growth and business development
BIMZELX patent protection runs to 2037; four additional growth drivers have patents into the early 2030s, supporting a growth agenda underway for two years.
Current assets could support growth after 2035 if successful; external additions in familiar disease areas can strengthen internal pillars and diversify long-term pipeline risk.
2026 and likely 2027 focus remains on executing launches, while IMIDomics, Antengene, Neurona and Candid add early-stage capabilities and modalities in established therapeutic areas.
Business development is shifting toward disease biology and longer-term benefit, including cell therapy for severe epilepsy and T-cell engagers aimed at immune reset in autoimmune disease.
BIMZELX outlook
Management sees potential for at least EUR 7bn in peak sales, citing superiority versus four competitors across psoriasis and psoriatic arthritis, and 150,000 patients with strong treatment experience.
Broader uptake may take time as prescribing habits, guidelines, PBM rebates and step edits do not always reward clinical superiority; management expects these barriers to ease over time.
Management sees potential across psoriasis, psoriatic arthritis and hidradenitis suppurativa; HS is an early-stage opportunity with compelling data and a growing market.
HS assessment should account for standard-of-care comparison, efficacy criteria, disease severity, placebo response and antibiotic use in trials.
HS diagnosis averages seven years after symptoms; management aims for earlier treatment and expects market leadership based on its data.
Neurology and pipeline differentiation
Myasthenia gravis is a larger, specialty market than previously understood, with varied prescribing practices and uneven uptake of anti-FcRn and anti-C5 therapies across geographies and hospitals.
The portfolio includes one anti-FcRn and one anti-C5, enabling treatment choice by patient profile; potential BCMA x CD3 T-cell engagers could add options for patients with high IgG levels.
Neurona cell therapy targets very severe temporal lobe epilepsy, including patients who cannot access surgery, with the aim of reducing seizures and supporting cognitive and brain development.
- BIMZELX® pairs sustained three-year HS benefits with expanding global commercial momentum.UCB
Investor update - Three-year data show bimekizumab delivers durable efficacy and safety in hidradenitis suppurativa.UCB
CMD 2025 presentation - Growth momentum continues with BIMZELX leadership, pipeline innovation, and strategic acquisitions.UCB
J.P. Morgan European Healthcare CEO Call Series - Upgraded guidance and strong BIMZELX momentum drive confidence in long-term growth.UCB
Bank of America Global Healthcare Conference - Revenue up 22% to €4.27B, EBITDA up 68%, and guidance upgraded on strong product growth.UCB
H1 2026 - Bimekizumab showed superior joint efficacy over risankizumab in psoriatic arthritis, influencing future care.UCB
Investor update - Acquisition of Candid Therapeutics boosts autoimmune pipeline with $2B deal and strong clinical assets.UCB
Acquisition presentation - Net sales up 35% year-over-year, driven by BIMZELX® and strong pipeline momentum.UCB
H2 2025 - Five launch products, stronger BIMZELX access and pipeline progress support the next growth phase.UCB
43rd Annual J.P. Morgan Healthcare Conference 2025
)
)
)
)
)
)
)
)